Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 13;8(28):eabn1382. doi: 10.1126/sciadv.abn1382

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 9. — (A) Survival probabilities were measured over time of control-treated, 3AP single compound–treated, and prexasertib-treated mice and mice treated with different concentration combinations of 3AP and prexasertib. Statistical analyses were performed using the log-rank (Mantel-Cox) test. (B) Time course analysis of the average mouse weight per 3AP treatment group included in this murine cell line xenograft study. (C) Time course analysis of the average mouse weight per 3AP, prexasertib, and combination treatment groups included in this murine cell line xenograft study. (D) Average tumor volume (TV) of the different 3AP treatment groups included in this murine cell line xenograft study. (E) Average TV of the 3AP, prexasertib, or combination treatment group included in this murine cell line xenograft study. (F) Time course analysis of the survival probabilities of the different 3AP treatment groups included in this murine cell line xenograft study. (G) Time course analysis of the survival probabilities of the 3AP, prexassertib, and combination treatment group included in the experiment. (H) Average TV of the 3AP, prexasertib, or combination treatment group included for the treatment schedule of a MYNC-nonamplified (p53 wild type) neuroblastoma PDX model. (I) Average TV of the 3AP, prexasertib, or combination treatment group included for the treatment schedule of a MYNC-amplified (p53 wild type, ALK R1275Q mutant) neuroblastoma PDX model. (J) Relative mean TV of the 3AP, prexasertib, or combination treatment group included for the treatment schedule of a MYNC-nonamplified (p53 wild type) neuroblastoma PDX model. (K) Relative mean TV of the 3AP, prexasertib, or combination treatment group included for the treatment schedule of a MYNC-amplified (p53 wild type, ALK R1275Q mutant) neuroblastoma PDX model. CR, complete response; PR, partial response; PD, progressive disease.